XML 209 R62.htm IDEA: XBRL DOCUMENT
v3.20.1

Non-Controlling Interests (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Disclosure of subsidiaries [line items] |
Details of non-controlling interests and movement | Details of non-controlling interests and movement at 31 December 2018 are as follows:
|  | Thousands of Euros
|  |  |  |  |  |  |  | Business |  |  |  |
|  |  |  |  |  |  |  | Combination / |  |  |  |
|  |  |  |  |  |  |  | Additions to |  |  |  |
|  | Balance at |  |  |  |  |  | Consolidated |  | Translation |  | Balance at
|  | 31/12/2017 |  | Additions |  | Disposals |  | Group |  | differences |  | 31/12/2018
Grifols (Thailand) Pte Ltd |  | 3,579 |  | 193 |  | (43) |  | — |  | 206 |  | 3,935
Grifols Malaysia Sdn Bhd |  | 1,372 |  | 326 |  | — |  | — |  | 37 |  | 1,735
Araclon Biotech, S.A. |  | (1,477) |  | (2,011) |  | — |  | — |  | — |  | (3,488)
Progenika Biopharma, S.A. |  | 880 |  | — |  | (871) |  | — |  | — |  | 9
VCN Bioscience, S.L |  | 421 |  | (281) |  | — |  | — |  | — |  | 140
Kiro Grifols , S.L. |  | 111 |  | (463) |  | — |  | — |  | — |  | (352)
Haema AG |  | — |  | — |  | — |  | 220,190 |  | — |  | 220,190
Biotest US Corporation |  | — |  | — |  | — |  | 249,691 |  | (810) |  | 248,881
|  | 4,886 |  | (2,236) |  | (914) |  | 469,881 |  | (567) |  | 471,050
Details of non-controlling interests and movement at 31 December 2019 are as follows:
|  | Thousands of Euros
|  | Balance at |  |  |  |  |  |  |  | Translation |  | Balance at
|  | 31/12/2018 |  | Additions |  | Disposals |  | Capital increases |  | differences |  | 31/12/2019
Grifols (Thailand) Pte Ltd |  | 3,935 |  | 193 |  | — |  | — |  | 421 |  | 4,549
Grifols Malaysia Sdn Bhd |  | 1,735 |  | 380 |  | — |  | — |  | 56 |  | 2,171
Araclon Biotech, S.A. |  | (3,488) |  | (1,975) |  | — |  | 5,892 |  | — |  | 429
Progenika Biopharma, S.A. |  | 9 |  | 0 |  | (9) |  | — |  | — |  | —
VCN Bioscience, S.L |  | 140 |  | (292) |  | — |  | — |  | — |  | (152)
Kiro Grifols , S.L. |  | (352) |  | (374) |  | — |  | 750 |  | — |  | 24
Haema AG |  | 220,190 |  | 5,881 |  | — |  | — |  | — |  | 226,071
Biotest US Corporation |  | 248,881 |  | 19,685 |  | — |  | — |  | 11,444 |  | 280,010
Grifols Diagnostic Solutions, Inc. (see note 2) |  | — |  | 1,510,547 |  | — |  | — |  | — |  | 1,510,547
|  | 471,050 |  | 1,534,045 |  | (9) |  | 6,642 |  | 11,921 |  | 2,023,649
Haema AG and Biotest US Corporation |
Disclosure of subsidiaries [line items] |
Summary of financial information on the non-controlling interests |
|  | Thousands of Euros |  | Thousands of Euros
|  | 31/12/2019 |  | 31/12/2018
|  | Haema AG |  | Biotest US Corp |  | Haema AG |  | Biotest US Corp
Non-current assets |  | 244,107 |  | 299,045 |  | 199,056 |  | 215,072
Current assets |  | 32,576 |  | 60,099 |  | 19,527 |  | 40,352
Total Assets |  | 276,683 |  | 359,144 |  | 218,583 |  | 255,424
Non-current liabilities |  | 22,226 |  | 56,425 |  | 98 |  | 8,766
Current liabilities |  | 28,386 |  | 22,709 |  | (1,705) |  | (2,223)
Total Liabilities |  | 50,612 |  | 79,134 |  | (1,607) |  | 6,543
Total equity |  | 226,071 |  | 280,010 |  | 220,190 |  | 248,881
|  | Thousands of Euros |  | Thousands of USD
|  | 31/12/2019 |  | 31/12/2019
Non-current assets |  | 3,416,366 |  | 3,834,871
Current assets |  | 273,259 |  | 306,734
Total Assets |  | 3,689,625 |  | 4,141,605
Non-current liabilities |  | 224,635 |  | 252,153
Current liabilities |  | 108,220 |  | 121,478
Total Liabilities |  | 332,855 |  | 373,631
Total equity |  | 3,356,770 |  | 3,767,974
GDS Group |
Disclosure of subsidiaries [line items] |
Summary of financial information on the non-controlling interests |
|  | Thousands of Euros |  | Thousands of Euros
|  | 31/12/2019 |  | 31/12/2018
|  | Haema AG |  | Biotest US Corp |  | Haema AG |  | Biotest US Corp
Non-current assets |  | 244,107 |  | 299,045 |  | 199,056 |  | 215,072
Current assets |  | 32,576 |  | 60,099 |  | 19,527 |  | 40,352
Total Assets |  | 276,683 |  | 359,144 |  | 218,583 |  | 255,424
Non-current liabilities |  | 22,226 |  | 56,425 |  | 98 |  | 8,766
Current liabilities |  | 28,386 |  | 22,709 |  | (1,705) |  | (2,223)
Total Liabilities |  | 50,612 |  | 79,134 |  | (1,607) |  | 6,543
Total equity |  | 226,071 |  | 280,010 |  | 220,190 |  | 248,881
|  | Thousands of Euros |  | Thousands of USD
|  | 31/12/2019 |  | 31/12/2019
Non-current assets |  | 3,416,366 |  | 3,834,871
Current assets |  | 273,259 |  | 306,734
Total Assets |  | 3,689,625 |  | 4,141,605
Non-current liabilities |  | 224,635 |  | 252,153
Current liabilities |  | 108,220 |  | 121,478
Total Liabilities |  | 332,855 |  | 373,631
Total equity |  | 3,356,770 |  | 3,767,974
|  | Thousands of Euros |  | Thousands of USD
|  | 31/12/2019 |  | 31/12/2019
Non-current assets |  | 3,416,366 |  | 3,834,871
Current assets |  | 273,259 |  | 306,734
Total Assets |  | 3,689,625 |  | 4,141,605
Non-current liabilities |  | 224,635 |  | 252,153
Current liabilities |  | 108,220 |  | 121,478
Total Liabilities |  | 332,855 |  | 373,631
Total equity |  | 3,356,770 |  | 3,767,974

X
- Definition The disclosure of detailed information about financial information of non-controlling interests. + References No definition available. + Details
Name: | grfs_DisclosureOfFinancialInformationOfNonControllingInterestsExplanatory
Namespace Prefix: | grfs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of non-controlling interests. + References No definition available. + Details
Name: | grfs_DisclosureOfNonControllingInterestsTableTextBlock
Namespace Prefix: | grfs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_HaemaAgAndBiotestUsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsDiagnosticsSolutionsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |